ISTA at hold by Jefferies

ISTA Pharmaceuticals Inc. was given a hold rating by Jefferies & Co., Inc. analyst David Windley on news of positive data on two pipeline products in the past three weeks (tobra/pred and Ecabet). ISTA's near-term outlook remains tied to its three marketed products, of which only Xibrom has managed to sustain sequential growth. ISTA reported promising preliminary results from a phase 2b trial of Ecabet, an investigational treatment for dry eye. Shares of the Irvine, Calif., pharmaceutical company were down 24 cents, or 3.50%, at $6.61 on volume of 49,624 shares versus the three-month running average of 131,773 shares. (Nasdaq: ISTA)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.